OGR

Lobbying for AMGEN USA INC

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $50,000.00 income · posted Jul 16, 2026

Lobbying activity 2

Medicare/Medicaid

Issues related to Medicare Part D and Medicare Part B reimbursement and coverage. Issues related to drug pricing. Issues related to biosimilar regulation. Issues related to 340B reform.

Taxation/Internal Revenue Code

Issues related to Puerto Rico.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.